BRPI1007620A2 - fosfodoestera 9a,composição metodo,metodo de aquisição de dados e imunoesnsaio para diagnostico, detecção, monitoramento ou prognostico do cancer de proposta, ou para diagnostico,detecção monitoramento ou prognostico da progressao do cancer de prostata. - Google Patents

fosfodoestera 9a,composição metodo,metodo de aquisição de dados e imunoesnsaio para diagnostico, detecção, monitoramento ou prognostico do cancer de proposta, ou para diagnostico,detecção monitoramento ou prognostico da progressao do cancer de prostata.

Info

Publication number
BRPI1007620A2
BRPI1007620A2 BRPI1007620A BRPI1007620A BRPI1007620A2 BR PI1007620 A2 BRPI1007620 A2 BR PI1007620A2 BR PI1007620 A BRPI1007620 A BR PI1007620A BR PI1007620 A BRPI1007620 A BR PI1007620A BR PI1007620 A2 BRPI1007620 A2 BR PI1007620A2
Authority
BR
Brazil
Prior art keywords
prognosis
diagnosis
monitoring
detection
phosphorester
Prior art date
Application number
BRPI1007620A
Other languages
English (en)
Portuguese (pt)
Inventor
David J P Henderson
Miles D Houslay
Ralf Hoffmann
Original Assignee
Koninkl Philips Electronics Nv
Univ Glasgow
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Koninkl Philips Electronics Nv, Univ Glasgow filed Critical Koninkl Philips Electronics Nv
Publication of BRPI1007620A2 publication Critical patent/BRPI1007620A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/44Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57434Specifically defined cancers of prostate
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/112Disease subtyping, staging or classification
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
BRPI1007620A 2009-05-12 2010-05-11 fosfodoestera 9a,composição metodo,metodo de aquisição de dados e imunoesnsaio para diagnostico, detecção, monitoramento ou prognostico do cancer de proposta, ou para diagnostico,detecção monitoramento ou prognostico da progressao do cancer de prostata. BRPI1007620A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09159957 2009-05-12
PCT/IB2010/052069 WO2010131193A1 (en) 2009-05-12 2010-05-11 Phosphodiesterase 9a as prostate cancer marker

Publications (1)

Publication Number Publication Date
BRPI1007620A2 true BRPI1007620A2 (pt) 2016-02-23

Family

ID=40847939

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1007620A BRPI1007620A2 (pt) 2009-05-12 2010-05-11 fosfodoestera 9a,composição metodo,metodo de aquisição de dados e imunoesnsaio para diagnostico, detecção, monitoramento ou prognostico do cancer de proposta, ou para diagnostico,detecção monitoramento ou prognostico da progressao do cancer de prostata.

Country Status (8)

Country Link
US (1) US9828604B2 (enExample)
EP (1) EP2430189B1 (enExample)
JP (1) JP5918694B2 (enExample)
KR (1) KR101695866B1 (enExample)
CN (1) CN102459645B (enExample)
BR (1) BRPI1007620A2 (enExample)
RU (1) RU2592668C2 (enExample)
WO (1) WO2010131193A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101675664B1 (ko) 2015-01-30 2016-11-11 경희대학교 산학협력단 전립선암 예방 또는 치료용 조성물
EP3303616B1 (en) 2015-05-29 2021-01-06 Koninklijke Philips N.V. Methods of prostate cancer prognosis
KR20180085387A (ko) 2016-12-27 2018-07-27 경희대학교 산학협력단 Trail 저항성 암 예방 또는 치료용 조성물
CN107119124B (zh) * 2017-05-10 2021-05-11 清华大学 一种检测待测样本中目标miRNA的含量的方法
KR102080887B1 (ko) * 2017-11-07 2020-02-24 고려대학교 산학협력단 Gcc2 유전자 또는 단백질을 과발현하는 엑소좀 기반 폐암 진단 또는 예후 예측용 마커 조성물
CN114349857B (zh) * 2022-03-15 2022-05-24 诺赛联合(北京)生物医学科技有限公司 一种Treg细胞制备方法以及在自身免疫性疾病方面的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5922595A (en) * 1997-12-09 1999-07-13 Incyte Pharmaceuticals, Inc. Cyclic GMP phosphodiesterase
US20090176722A9 (en) 2000-01-28 2009-07-09 Shiv Srivastava Androgen-regulated PMEPA1 gene and polypeptides
AU2003301894A1 (en) 2002-11-08 2004-06-07 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human phosphodiesterase 4d (pde4d)
WO2004053494A1 (en) * 2002-12-09 2004-06-24 Bayer Healthcare Ag DIAGNOSTICS AND THERAPEUTICS FOR DISEASES ASSOCIATED WITH HUMAN PHOSPHODIESTERASE 9a2 (PDE9a2)
AU2003288171A1 (en) * 2002-12-09 2004-06-30 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human phosphodiesterase 9a3 (pde9a3)
AU2003289894A1 (en) * 2002-12-09 2004-06-30 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human phosphodiesterase 9a4 (pde9a4)
AU2003283427A1 (en) 2002-12-09 2004-06-30 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with phosphodiesterase 9a1 (pde9a1)
US7405237B2 (en) 2004-07-28 2008-07-29 Celgene Corporation Isoindoline compounds and methods of their use
EP2074225B1 (en) 2006-10-10 2014-12-03 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Prostate cancer-specific alterations in erg gene expression and detection and treatment methods based on those alterations

Also Published As

Publication number Publication date
CN102459645B (zh) 2023-05-30
EP2430189A1 (en) 2012-03-21
US20120065100A1 (en) 2012-03-15
JP2012526543A (ja) 2012-11-01
CN102459645A (zh) 2012-05-16
WO2010131193A1 (en) 2010-11-18
US9828604B2 (en) 2017-11-28
JP5918694B2 (ja) 2016-05-18
KR20120034650A (ko) 2012-04-12
KR101695866B1 (ko) 2017-01-13
EP2430189B1 (en) 2018-11-21
WO2010131193A8 (en) 2011-12-08
RU2592668C2 (ru) 2016-07-27
RU2011150291A (ru) 2013-06-20

Similar Documents

Publication Publication Date Title
WO2009037572A3 (en) Biomarker combinations for colorectal cancer
BR112013000745A2 (pt) "método para diagnosticar ou detectar câncer colorretal em um individuo, método de tratamento e método para monitorar a eficacia de tratamento de câncer colorretal em um indivíduo"
BRPI1007093A2 (pt) fosfodiesterase 4d7 uso de pde4d7; composição metodo, metodo de aquisição de dados imunoensaio para detectar diagnosticar, monitorar ou prognosticar cancer de prostata ou para diagnosticar, detectar monitorar ou prognosticar progressao do cancer
BRPI0807499A2 (pt) Aparelho e método para aquisição e/ou detecção automática de dados.
WO2011139721A8 (en) Cancer biomarkers and methods of use thereof
WO2010096154A3 (en) Compositions and methods for diagnosis and prognosis of colorectal cancer
EP2611941A4 (en) GENESIS OF CANCER DIAGNOSIS AND PROGNOSIS
WO2010017515A3 (en) Breast cancer specific markers and methods of use
WO2012012725A3 (en) Methods of detecting diseases or conditions using phagocytic cells
BRPI1012101A2 (pt) sistemas e método de compartilhamento de dados.
WO2011088149A3 (en) Methods for predicting response of triple-negative breast cancer to therapy
BR112014009643A2 (pt) métodos para diagnosticar ou detectar neoplasia colorretal em um sujeito humano, biomarcador para progressão de doença e kits para um diagnóstico de neoplasia colorretal
BRPI0807695A2 (pt) Aparelho e método para aquisição e/ou detecção automàtica de dados
BRPI0807500A2 (pt) Aparelho e método para aquisição e/ou detecção automática de dados
WO2010129934A3 (en) Methods and compositions for diagnosis of thyroid conditions
BR112013006683A2 (pt) diagnóstico de câncer de mama
WO2009036427A3 (en) Prostate cancer biomarkers
WO2012048113A3 (en) Biomarkers of cancer
BR112012030515A2 (pt) sistema para determinar o teor de asfalteno de óleo bruto, e método para determinar o teor de asfalteno de óleo bruto.
WO2008097908A3 (en) Methods of diagnosing and prognosing lung cancer
HK1220253A1 (zh) 诊断前列腺癌症的方法
BRPI1007620A2 (pt) fosfodoestera 9a,composição metodo,metodo de aquisição de dados e imunoesnsaio para diagnostico, detecção, monitoramento ou prognostico do cancer de proposta, ou para diagnostico,detecção monitoramento ou prognostico da progressao do cancer de prostata.
IT1397197B1 (it) Veicolo battipista e relativo metodo di controllo.
HK1259001A1 (zh) 癌症的预後和诊断方法
BRPI1014113A2 (pt) método de processamento de dados sísmicos com base em campo de onda , e, sistema configurado para realizar processamento de dados sísmicos com base em campo de onda.

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: THE UNIVERSITY COURT OF THE UNIVERSITY OF GLASGOW

B25G Requested change of headquarter approved

Owner name: THE UNIVERSITY COURT OF THE UNIVERSITY OF GLASGOW

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]